Protara Therapeutics, Inc.

NasdaqGM TARA

Protara Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 142.90

Protara Therapeutics, Inc. Price to Sales Ratio (P/S) is 142.90 on January 14, 2025, a 675.39% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Protara Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 177.89 on January 07, 2025, which is 24.48% above the current Price to Sales Ratio (P/S).
Protara Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 16.25 on January 22, 2024, which is -88.63% below the current Price to Sales Ratio (P/S).
Protara Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 49.45.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: TARA

Protara Therapeutics, Inc.

CEO	Mr. Jesse Shefferman
IPO Date	Oct. 22, 2014
Location	United States
Headquarters	345 Park Avenue South
Employees	26
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Key trends

Past 5 years